The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study

被引：0
|
作者：
Watanabe, Takuya
Nakayama, Goro
Ishigure, Kiyoshi
Hayashi, Naomi
Yaguchi, Toyohisa
Kojima, Hiroshi
Tsuboi, Kenji
Ito, Akihiro
Deguchi, Tomohiro
Sekiya, Masanori
Tanaka, Chie
Ando, Yuichi
Ohashi, Norifumi
Kodera, Yasuhiro
机构：
[1] Komaki City Hosp, Komaki, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Nagoya, Aichi 4648601, Japan
[3] Konan Kosei Hosp, Konan, Aichi, Japan
[4] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan
[5] Kainan Hosp, Yayomi, Japan
[6] Aichi Canc Ctr Hosp, Okazaki, Aichi, Japan
[7] Tosei Hosp, Seto, Japan
[8] Toki City Hosp, Toki, Gifu, Japan
[9] Tajimi Prefectual Hosp, Tajimi, Japan
[10] Nakatsugawa City Hosp, Nakatsugawa, Japan
[11] Nagoya Grad Sch Med, Nagoya, Aichi, Japan
[12] Nagoya Univ Hosp, Nagoya, Aichi, Japan
[13] Aichi Med Univ, Nagakute, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
564
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PRELIMINARY EFFICACY, SAFETY AND OPERABILITY OF BEVACIZUMAB(BV) PLUS CAPECITABINE PLUS OXALIPLATIN (XELOX) AS FIRST-LINE THERAPY IN JAPANESE PATIENTS (PTS) WITH INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Yamaguchi, K.
    Boku, N.
    Kato, K.
    Komatsu, Y.
    Muro, K.
    Hamamoto, Y.
    Sato, A.
    Koizumi, W.
    Mizunuma, N.
    Takiuchi, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [32] A phase II study of capecitabine plus oxaliplatin (XELOX)A new first-line option in metastatic colorectal cancer
    Thomas Makatsoris
    Haralabos P. Kalofonos
    Gerasimos Aravantinos
    Christos Papadimitriou
    Efstathios Kastritis
    Sotirios K. Rigatos
    Nikolaos Xiros
    Theodore Petsas
    Theofanis Economopoulos
    Athanassios K. Sakadamis
    George Fountzilas
    International Journal of Gastrointestinal Cancer, 2005, 35 (2): : 103 - 109
  • [33] Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.
    Xu, Rui-Hua
    Wang, Feng
    Wang, Zi-Xian
    Peng, Junjie
    Liang, Xinjun
    Cheng, Ying
    Deng, Yanhong
    Chen, Kehe
    Zhang, Mingjun
    Zhang, Jingdong
    Wang, Wei
    Cao, Bangwei
    Jin, Yongdong
    Sun, Meili
    Lin, Yuan
    Luo, Suxia
    Li, Zhen
    Yang, Liu
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 170 - 170
  • [34] XELOX AND BEVACIZUMAB AS FIRST-LINE TREATMENT IN FIT ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER: THE BOXE STUDY
    Rosati, Gerardo
    Avallone, Antonio
    Aprile, Giuseppe
    Butera, Alfredo
    De Pauli, Federica
    Reggiardo, Giorgio
    Bilancia, Domenico
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [35] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
    Shaotang Li
    Pan Dr Chi
    BioDrugs, 2011, 25 : 43 - 50
  • [36] CAPECITABINE PLUS OXALIPLATIN (XELOX REGIMEN) A SAFE AND ACTIVE FIRST-LINE TREATMENT FOR CUBAN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Lami, Leonardo
    Diaz, Carlos
    Areces, Fernando
    Lence, Juan
    Arbesu, Maria
    ANNALS OF ONCOLOGY, 2011, 22 : v95 - v96
  • [37] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [38] Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer
    Grande, Carlos
    Quintero, Guillermo
    Candamio, Sonia
    Paris Bouzas, Lorena
    Jose Villanueva, Maria
    Campos, Begona
    Gallardo, Elena
    Alvarez, Elena
    Casal, Joaquin
    Ramon Mel, Jose
    JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (02) : 114 - 121
  • [39] OXALIPLATIN STOP-AND-GO STRATEGY WITH ORAL S-1 MAINTENANCE THERAPY IN ADVANCED COLORECTAL CANCER; CCOG-0704 STUDY
    Nakayama, G.
    Kodera, Y.
    Fujii, T.
    Nakao, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 215 - 215
  • [40] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
12345